RFK Jr. Baffles with Math at Senate Hearing

A man in a suit speaking into a microphone on stage

RFK Jr.’s defense of Trump’s “600%” drug-price cuts turned a Senate hearing into a lesson on why Americans don’t trust Washington’s numbers anymore.

Story Snapshot

HHS Secretary Robert F. Kennedy Jr. told senators President Trump has “his own way of calculating” drug-price drops tied to the TrumpRx initiative.
RFK Jr. cited an example of a drug falling from $600 to $10 and described it as a “600% reduction,” a claim critics say misuses basic percentage math.
Democrats, led by Sen. Elizabeth Warren, used the exchange to argue the administration is overselling results while failing to show broad, verifiable savings.
The dispute highlights a deeper bipartisan frustration: federal agencies often communicate major economic claims in ways that feel political rather than precise.

What RFK Jr. Said Under Oath—and Why It Matters

Robert F. Kennedy Jr., serving as President Donald Trump’s HHS secretary, drew headlines after an April 22 Senate Finance Committee hearing in which he defended Trump’s repeated claim that TrumpRx slashed prescription drug prices by as much as 600%. Pressed by Sen. Elizabeth Warren, RFK Jr. said Trump uses a “different way of calculating percentages,” offering a $600-to-$10 example to justify the figure. The clip spread quickly online.

Math is not partisan, and that is the core vulnerability of this defense. A price drop from $600 to $10 is a large reduction, but it is not a 600% reduction under the standard formula used in budgeting, contracting, and consumer disclosures. Critics argue the exchange undercuts credibility because it sounds like the government is redefining terms midstream to claim bigger wins. For families facing high pharmacy bills, precision matters.

The Math Dispute Is Really a Trust Dispute

The factual point is straightforward: percentage reduction is typically calculated as (old minus new) divided by old, then multiplied by 100. Using the $600-to-$10 example cited in the hearing, that yields roughly a 98% reduction, not 600%. Observers quoted in coverage argued you cannot “redefine” the calculation to produce a more dramatic headline figure. When agencies blur basic arithmetic, oversight hearings become less about policy and more about credibility.

That credibility gap lands on both parties because it feeds an existing public suspicion that government officials spin outcomes instead of reporting them. Conservatives have long criticized Washington for wasteful spending and PR-heavy “wins” that don’t show up in household budgets. Many liberals share a parallel frustration: they see political messaging used to obscure whether programs actually help patients. In a country where prescription costs remain a top-pocketbook issue, vague claims invite backlash from all sides.

What We Know—and Don’t Know—About TrumpRx Savings

Outside the hearing exchange, the hardest question is empirical: what documented, systemwide savings can the administration show? Criticism cited in the research argues there is “no evidence” TrumpRx delivered broad reductions for the “vast majority” of patients, and that the initiative may function more as messaging than measurable reform. The available sources here are largely adversarial to the administration, so readers should treat the claims as disputed unless HHS releases verifiable comparisons.

Still, the political risk for Republicans is real even in unified government. When the GOP controls the House and Senate, voters expect results, not arguments over definitions. If the administration can demonstrate specific, audited price declines—by drug, payer type, and patient out-of-pocket cost—it can rebut critics on substance. If it cannot, Democrats will keep framing TrumpRx as an exaggerated promise, and the story will become about competence rather than ideology.

Congressional Oversight and the Bigger Pattern in Washington

The April 22 exchange also fits into a broader 2026 oversight environment, with Democrats using hearings to challenge RFK Jr. on qualifications and agency priorities while Republicans defend the administration’s direction. That dynamic is familiar: each side uses clips to energize its base. But the public’s deeper complaint is that oversight often produces viral moments instead of clear answers—especially on issues like healthcare pricing where Americans want plain language and proof.

RFK Jr. Defends Trump’s Bogus Math: ‘Has a Different Way of Calculating’ https://t.co/IZLPqqjgIS

— Mediaite (@Mediaite) April 23, 2026

For conservatives who want limited, competent government, the takeaway is less about one awkward soundbite and more about institutional discipline. Agencies that make sweeping affordability claims should be prepared to show their work, using standard definitions and transparent data. For liberals who worry about unequal access and corporate influence, the same transparency is essential to evaluate whether reforms are real or rhetorical. Either way, when leaders defend questionable math, they hand ammunition to the “deep state” distrust that now spans left and right.